StreetInsider.com News Articles

Form 8-K/A Ridgepost Capital, Inc. For: Jun 22

Fri, 04 Sep 2026 11:33:00 -0400

si-local-file:///var/storage/secattach/20260904/27028716.html

Form 8-K/A Ridgepost Capital, Inc. For: Jun 22

Fri, 04 Sep 2026 11:33:00 -0400

si-local-file:///var/storage/secattach/20260904/27028716.html

Radient Pharmaceuticals (RPC) PT Lowered to $15 at Oppenheimer

Thu, 27 Aug 2026 08:12:23 -0400

Oppenheimer lowered its price target on Radient Pharmaceuticals (NYSE: RPC) to $15.00 (from $16.00) while maintaining a Outperform rating.

Ridgepost Capital to Sponsor IPEM Global 2026

Tue, 11 Aug 2026 07:00:00 -0400

DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Ridgepost Capital, Inc. (“Ridgepost Capital”) (NYSE: RPC), a leading private markets solutions provider, today announced details regarding its sponsorship at IPEM Global 2026, taking place September 8–10 at the Palais des Congrès in Paris. Ridgepost Capital attendees will include Luke Sarsfield, Chairman and Chief Executive Officer, and Sarita Jairath, EVP and Global Head of Client Solutions.

Representatives from Ridgepost Capital’s strategies – Bonaccord Capital Partners, Qualitas Funds, RCP Advisors, and TrueBridge

Ridgepost Capital to Sponsor IPEM Global 2026

Tue, 11 Aug 2026 07:00:00 -0400

Representatives from Ridgepost Capital’s strategies – Bonaccord Capital Partners, Qualitas Funds, RCP Advisors, and TrueBridge

Ridgepost Capital to Sponsor IPEM Global 2026

Tue, 11 Aug 2026 07:00:00 -0400

Representatives from Ridgepost Capital’s strategies – Bonaccord Capital Partners, Qualitas Funds, RCP Advisors, and TrueBridge

Ridgepost Capital to Sponsor IPEM Global 2026

Tue, 11 Aug 2026 07:00:00 -0400

Representatives from Ridgepost Capital’s strategies – Bonaccord Capital Partners, Qualitas Funds, RCP Advisors, and TrueBridge

Radient Pharmaceuticals (RPC) PT Lowered to $11 at Barclays

Mon, 10 Aug 2026 04:22:48 -0400

Barclays lowered its price target on Radient Pharmaceuticals (NYSE: RPC) to $11.00 (from $12.00) while maintaining a Overweight rating.

Form 10-Q Ridgepost Capital, Inc. For: Jun 30

Fri, 07 Aug 2026 15:48:00 -0400

http://archive.fast-edgar.com/20260807/AK2V422FZZ2RU2Z2229S2CYQ9C3HZZ223282

Filed on: August 7, 2026

Form 10-Q Ridgepost Capital, Inc. For: Jun 30

Fri, 07 Aug 2026 15:48:00 -0400

http://archive.fast-edgar.com/20260807/AK2V422FZZ2RU2Z2229S2CYQ9C3HZZ223282

Filed on: August 7, 2026

Form 10-Q Ridgepost Capital, Inc. For: Jun 30

Fri, 07 Aug 2026 15:48:00 -0400

http://archive.fast-edgar.com/20260807/AK2V422FZZ2RU2Z2229S2CYQ9C3HZZ223282

Filed on: August 7, 2026

Form SCHEDULE 13G/A Ridgepost Capital, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260806/26881342.html

Form SCHEDULE 13G/A Ridgepost Capital, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260806/26881342.html

Form SCHEDULE 13G/A Ridgepost Capital, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260806/26881342.html

Radient Pharmaceuticals (RPC) PT Lowered to $16 at Oppenheimer

Thu, 06 Aug 2026 08:37:51 -0400

Oppenheimer lowered its price target on Radient Pharmaceuticals (NYSE: RPC) to $16.00 (from $17.00) while maintaining a Outperform rating.

Form 8-K Ridgepost Capital, Inc. For: Aug 05

Wed, 05 Aug 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26869707.html

Form 8-K Ridgepost Capital, Inc. For: Aug 05

Wed, 05 Aug 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26869707.html

Form 8-K Ridgepost Capital, Inc. For: Aug 05

Wed, 05 Aug 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26869707.html

Radient Pharmaceuticals (RPC) Tops Q2 EPS by 1c

Wed, 05 Aug 2026 06:21:46 -0400

Radient Pharmaceuticals (NYSE: RPC) reported Q2 EPS of $0.24, $0.01 better than the analyst estimate of $0.23. Revenue for the quarter came in at $80.9 million versus the consensus estimate of $79.89 million.

For earnings history and earnings-related data on Radient Pharmaceuticals (RPC) click here.

Ridgepost Capital Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 06:00:00 -0400

DALLAS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ridgepost Capital, Inc. (NYSE: RPC) (“Ridgepost Capital”), a leading private markets solutions provider, today reported financial results for the second quarter ended June 30, 2026.

A presentation of the quarterly financials is available at https://ir.ridgepostcapital.com/quarterly-results.

“Ridgepost Capital delivered another strong quarter of results, highlighting the durability of our fee-based model as well as the breadth of our investment platform,” said Luke Sarsfield, Ridgepost Capital Chairman and Chief Executive Officer. “We achieved important milestones during the quarter, including surpassing $50 billion in AUM

Ridgepost Capital Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 06:00:00 -0400

A presentation of the quarterly financials is available at https://ir.ridgepostcapital.com/quarterly-results.

Ridgepost Capital Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 06:00:00 -0400

A presentation of the quarterly financials is available at https://ir.ridgepostcapital.com/quarterly-results.

Ridgepost Capital Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 06:00:00 -0400

A presentation of the quarterly financials is available at https://ir.ridgepostcapital.com/quarterly-results.

Form SCHEDULE 13G Ridgepost Capital, Inc. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:22:00 -0400

si-local-file:///var/storage/secattach/20260729/26834342.html

Form SCHEDULE 13G Ridgepost Capital, Inc. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:22:00 -0400

si-local-file:///var/storage/secattach/20260729/26834342.html